<SEC-DOCUMENT>0001558370-24-004015.txt : 20240327
<SEC-HEADER>0001558370-24-004015.hdr.sgml : 20240327
<ACCEPTANCE-DATETIME>20240327090027
ACCESSION NUMBER:		0001558370-24-004015
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240327
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240327
DATE AS OF CHANGE:		20240327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		24785985

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>glyc-20240327x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.5.0.8 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/26/2024 10:15:43 PM -->
<!-- iXBRL Library version: 1.0.8703.18788 -->
<!-- iXBRL Service Job ID: 40a78a22-99d9-488c-8bae-4e70580073c7 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:glyc="http://www.glycomimetics.com/20240327" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" name="dei:EntityCentralIndexKey" id="Tc_OTJ1yVZyj06FHXL-gT8HRA_2_1">0001253689</ix:nonNumeric><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" name="dei:AmendmentFlag" id="Tc_QuxbPFNSTkKIKayAtTETFg_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="glyc-20240327.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-27</xbrli:startDate><xbrli:endDate>2024-03-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-top:9pt double #000000;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><a id="_0a72fd11_d0c7_486d_a868_6d91db0833f2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;">UNITED STATES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;letter-spacing:-0.1pt;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">FORM </b><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" name="dei:DocumentType" id="Narr_j1yO9H9iNke32vRcZxm-lA"><b style="font-weight:bold;letter-spacing:-0.1pt;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Pursuant to Section 13 or 15(d) of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;">Date of Report (Date of earliest event reported):</b><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_y8Z8T9oZdUODH-3Cok_SrA"><b style="font-size:9pt;font-weight:bold;">March 27, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" name="dei:EntityRegistrantName" id="Narr_FTgLSYEw3UiqE6yvlu9Uaw"><b style="font-weight:bold;letter-spacing:-0.1pt;">GlycoMimetics, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Exact name of registrant as specified in its charter)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_e1f4de58_61bd_4709_b865_8049cd6378dd"></a><a id="Tc_70D99925dECzUdUjg33_4g_2_0"></a><a id="Tc_L4SSo-KMR0i_NslvkTLtxw_2_2"></a><a id="Tc_527uMGUwBkKGbc7--onKGA_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_p3_kJjosNkOWD3walENONg_1_0"><b style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" name="dei:EntityFileNumber" id="Tc_dlutGaub7k2gJJcBNaOKdg_1_2"><b style="font-size:9pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">001-36177</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" name="dei:EntityTaxIdentificationNumber" id="Tc_BS2pV-ulfEGwZp45lrVXZg_1_4"><b style="font-size:9pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">06-1686563</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(State or other jurisdiction of</span> <span style="letter-spacing:-0.1pt;">incorporation)</span></p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Commission File Number)</span></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(IRS Employer</span><br/><span style="letter-spacing:-0.1pt;">Identification No.)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" name="dei:EntityAddressAddressLine1" id="Narr_WGj3rc7fwk642pLIxahNYg"><b style="font-size:9pt;font-weight:bold;">9708 Medical Center Drive</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" name="dei:EntityAddressCityOrTown" id="Narr_KbV90nSDMkWi6GWqSoxEZw"><b style="font-size:9pt;font-weight:bold;">Rockville</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" name="dei:EntityAddressStateOrProvince" id="Narr_GCI8QYqFpkWmyv1bS7c7iQ"><b style="font-size:9pt;font-weight:bold;">MD</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" name="dei:EntityAddressPostalZipCode" id="Narr_mcIuUwnc8E2tPp50DEFpGQ"><b style="font-size:9pt;font-weight:bold;">20850</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Address of principal executive offices, including zip code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" name="dei:CityAreaCode" id="Narr_GVdFfEy3t0CYFDc85yh6lQ"><b style="font-size:9pt;font-weight:bold;">240</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" name="dei:LocalPhoneNumber" id="Narr_EZTOlT5KkEC5jjKmy6qmug"><b style="font-size:9pt;font-weight:bold;">243-1201</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Registrant&#8217;s telephone number, including area code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Former name or former address, if changed since last report)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_AG34YLuW0USB1KupYYlyLQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_RHSZuEgflUyw_bl6-KfFIw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';font-size:9pt;"> </span><span style="font-size:9pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_FgPYo04JeUqcJEx0rAy1wg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';font-size:9pt;"> </span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_zJKno4X0Z06NnCG2e9v30A"><span style="font-family:'Segoe UI Symbol';font-size:9pt;letter-spacing:0pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;letter-spacing:0pt;"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_815aaab8_f3ad_460f_b7c2_43bd0f552b4c"></a><div style="margin-left:0pt;"><a id="Tc_ik17HR7TXUuUNcgf5vzRRg_1_0"></a><a id="Tc_w61yABIi0EuMdGhYh8Na9w_1_1"></a><a id="Tc__Myr5gr_OU2U6gHvOnxI-Q_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:97.58%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title of each class</b></p></td><td style="vertical-align:top;width:22.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:44.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" name="dei:Security12bTitle" id="Tc_kbSrr_hdEEG1rxp-XlrkFQ_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:22.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" name="dei:TradingSymbol" id="Tc_v2k4bQqCmkG5fUmV-OsrcQ_2_1"><span style="font-size:9pt;">GLYC</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:44.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_5v5501SSL0ukVXumz4uCig_2_2"><span style="font-size:9pt;">The Nasdaq Stock Market</span></ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_G41F5W6LHkiBAx-YJM3q7Q"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:97.58%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> <span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-bottom:9pt double #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Courier New';line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:81.18%;border:0;margin:30pt 9.41% 30pt 9.41%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_6ae6eebd_08cb_4ec5_9034_e675a12c6c88"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 2.02 &#160;</b></span><b style="font-weight:bold;">Results of Operations and Financial Condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On March 27, 2024, GlycoMimetics, Inc. (the &#8220;<span style="font-style:italic;font-weight:bold;">Company</span><i style="font-style:italic;">&#8221;)</i><span style="font-style:italic;font-weight:bold;"> </span>issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-style:italic;font-weight:bold;">Exchange Act</span>&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company&#8217;s filings under the Securities Act of 1933, as amended (the &#8220;<span style="font-style:italic;font-weight:bold;">Securities Act</span>&#8221;), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9.01</b></span><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (d)&#160;Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:88.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></td></tr><tr style="height:3.55pt;"><td style="vertical-align:top;width:10.27%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">9</span>9.1</p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20240327xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated March 27, 2024, &#8220;GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023&#8221;</span></a> </p></td></tr><tr><td style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.05pt;margin:0pt;"><span style="font-size:0.05pt;visibility:hidden;">&#8203;</span></p><a id="_b63a899d_8572_44e2_92f7_f1598448e000"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;text-align:justify;text-indent:37.05pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.7pt;padding-right:0.7pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></div></div></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GLYCOMIMETICS, INC.</p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="letter-spacing:-0.1pt;">By:&#160;&#160;</span></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">/s/ </span>Brian M. Hahn</p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:-0.1pt;white-space:pre-wrap;">Date:  March 27, </span>2024</p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian M. Hahn<br/>Senior Vice President and Chief Financial Officer </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>glyc-20240327xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 3/26/2024 10:15:41 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 99.1</b></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:justify;text-transform:uppercase;margin:0pt 41.75pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"><img src="glyc-20240327xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:58.4pt;width:271pt;"></b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><a name="_Hlk162356841"></a><b style="font-weight:bold;">GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and </b><a name="_cp_change_1"></a><b style="font-weight:bold;">Full Year</b><b style="font-weight:bold;"> 2023</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) to be reported in Q2 2024 </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">New Drug Application (NDA) for uproleselan to be submitted to the U.S. Food and Drug Administration (FDA) by end of 2024</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_3"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> if</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> outcome of R/R AML pivotal study</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_4"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> is </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">positive</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Phase 1a study of GMI-1687, a highly potent E-selectin antagonist with an initial focus on sickle cell disease (SCD), met its primary and secondary endpoints</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">The </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_6"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">company</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> has entered into a research collaboration for GMI-1687 with the </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_8"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">ASH Research Collaborative (ASH RC), a non-profit organization established by</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> the American Society of Hematology (ASH) </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Conference call and webcast to be hosted on March 27, 2024, at 8:30 a.m. ET. </font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">ROCKVILLE, Md.--(BUSINESS WIRE) &#8211; March 27, 2024-- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2023. Cash and cash equivalents as of December 31, 2023, were $41.8 million.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;">&#8220;With <a name="_cp_change_9"></a>the time-based analysis imminent for our pivotal Phase 3 study of uproleselan in R/R AML, we are laser-focused on delivering the topline results in Q2 and excited about the possibility of <a name="_cp_change_11"></a>submitting an NDA before year-end. This large, randomized, global trial now has a median follow-up of more than three years, which is <a name="_cp_change_12"></a>r<a name="_cp_change_13"></a>emarkable in R/R AML, and could demonstrate the potential of uproleselan to become a new standard of care for a disease with limited treatment options and high unmet need,&#8221;&#160;said Harout Semerjian, Chief Executive Officer of GlycoMimetics. &#8220;We are also pleased to announce our agreement with the ASH RC for GMI-1687, further validating the potential of this highly potent E-selectin antagonist for the treatment of sickle cell disease. We remain deeply committed to bringing life-changing treatments to patients and look forward to sharing more important updates in the coming months.&#8221;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Operational Highlights</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">Uproleselan</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Hlk130828815"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In June 2023, GlycoMimetics announced FDA clearance of a protocol amendment to the company&#8217;s pivotal Phase 3 study of uproleselan for R/R AML. This amendment provides for a time-based analysis of the primary endpoint of overall survival after a defined cutoff date, if the 295 survival events of the originally planned event-driven analysis have not been observed by that date. With adoption of the time-based analysis, the company expects to report topline results in Q2 2024. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">A total of 388 patients across 70 sites in nine countries were </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_14"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">enrolled and </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">randomized in the pivotal Phase 3 trial, which has a primary endpoint of overall survival</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_16"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">. The time-based analysis</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> dataset </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_18"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">will reflect</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> a median follow-up in patients remaining on study of more than three years, underscoring the potential utility of uproleselan in R/R AML. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">The National Cancer Institute (NCI) Alliance for Clinical Trials in Oncology will conduct an analysis of event-free survival in 267 patients </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_21"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">enrolled and </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">randomized </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_23"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> its Phase 2/3 clinical trial (NCI protocol A041701) evaluating uproleselan in newly diagnosed older adults with AML who are fit for chemotherapy. Enrollment of the Phase 2 portion of the study was completed in December 2021. The company reiterates that when available, it will share these results.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><a name="_Hlk140751440"></a><font style="margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">GMI-1687</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In August 2023, GlycoMimetics initiated a Phase 1a single-center, double-blind, randomized, placebo-controlled, sequential, single ascending dose trial in healthy adult volunteers. The study enrolled 40 subjects. Eligible subjects received a single dose of GMI-1687 or placebo (6:2 ratio) via subcutaneous injection. In January 2024, the company announced that the study met its primary and secondary endpoints of safety/tolerability and pharmacokinetics. There were no dose-limiting toxicities or other safety signals. Potentially therapeutic plasma levels that may alleviate vaso-occlusive events (VOE) were achieved at multiple dose levels after a single injection. Full study results of this Phase 1a first-in-human trial of GMI-1687 will be presented at an upcoming medical meeting. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">GlycoMimetics announced today that it has entered into a research agreement with the </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_25"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">ASH RC and its </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Sickle Cell Disease </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_27"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Research</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> Network. This collaboration will obtain feedback on the GMI-1687 clinical development plan from </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_30"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">people living with sickle cell disease</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> and therapeutic area experts. ASH RC fosters partnerships to accelerate progress and improve outcomes for </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_31"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">people living with </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">SCD</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_32"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-line:line-through;text-decoration-style:solid;"> </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">by expediting therapeutics development and generating high-quality evidence to support clinical decision-making.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Corporate Update</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">GlycoMimetics strengthened its leadership team by appointing Shantha Tyavanagimatt, Ph.D., as Senior Vice President of Technical Operations.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;background:#ffffff;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Fourth Quarter and </b><a name="_cp_change_34"></a><b style="font-weight:bold;">Full Year</b><b style="font-weight:bold;"> 2023 Financial Results</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Cash position: As of&#160;December 31, 2023,&#160;GlycoMimetics&#160;had cash and cash equivalents of&#160;$41.8 million</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_36"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">,</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;compared to&#160;$47.9 million&#160;as of&#160;December 31, 2022.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 18pt;"><font style="line-height:1.37;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">R&amp;D Expenses: The company&#8217;s research and development expenses decreased to&#160;$5.3 million&#160;for the quarter ended&#160;December 31, 2023, compared to&#160;$5.9 million&#160;for the fourth quarter of 2022. Research and development expenses for the year ended&#160;December 31, 2023,&#160;decreased to $20.1 million</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_39"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">,</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> compared to&#160;$28.4 million&#160;in the prior year. These decreases were due to lower clinical development expenses </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_41"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">for the</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> global Phase 3 clinical trial of uproleselan in individuals with relapsed/refractory AML, and decreased manufacturing costs</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_43"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> due to the completion of engineering and validation batches for uproleselan</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">, partially offset by the Phase 1 clinical trial of GMI-1687.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="line-height:1.37;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">G&amp;A Expenses: The company&#8217;s general and administrative expenses decreased to&#160;$4.3 million&#160;for the quarter ended&#160;December 31, 2023,&#160;compared to&#160;$4.7 million&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">for the fourth quarter of 2022.   General and administrative expenses for the year ended&#160;December 31, </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_47"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">2023, </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">increased </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_48"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">slightly </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">to&#160;$19.2 million</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_50"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">,</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">&#160;compared to&#160;$19.1 million&#160;in the prior year. </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_52"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">The overall increase was</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> due to higher personnel-related expenses</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_53"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">,</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> offset </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_change_54"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">in part </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">by a decrease in external consulting expenses.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="line-height:1.37;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Shares Outstanding: Shares of common stock outstanding as of&#160;December 31, 2023, were 64,393,744.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">Conference Call Information</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="white-space:pre-wrap;">The company will host a conference call and webcast today at 8:30 a.m. ET.  To access the call by phone, please go to this</font> registration link and you will be provided with dial in details.&#160;Participants are encouraged to connect 15 minutes in advance of the scheduled start time. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;">A live webcast of the call will be available on the &#8220;Investors&#8221; tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="display:inline-block;width:173.5pt;"></font><font style="margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">About Uproleselan</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-weight:bold;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Discovered and developed by GlycoMimetics, uproleselan is an investigational, first-in-class E-selectin antagonist. Uproleselan (yoo&#8217; pro le&#8217;se lan) <a name="_cp_change_57"></a>is currently <a name="_cp_change_58"></a>being evaluated in a broad development program<a name="_cp_change_59"></a>, including a late-stage Phase 3 trial in acute myeloid leukemia (AML<a name="_cp_change_61"></a>), GlycoMimetics has received Breakthrough Therapy and Fast Track designations from the FDA and Breakthrough Therapy designation from the Chinese National Medical Products Administration for <a name="_cp_change_63"></a>uproleselan as a potential treatment <a name="_cp_change_65"></a>for adult AML patients with relapsed or refractory disease. Uproleselan is designed to block E-selectin binding and stimulation of myeloid cells. E-selectin is expressed on the surface of blood vessels, and its binding to myeloid cells <a name="_cp_change_67"></a>is believed to confer a pro-survival effect. Uproleselan is intended to enable a novel approach to disrupting established mechanisms of leukemic cell resistance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><a name="_Hlk140751818"></a><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About GMI-1687</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Discovered and developed by&#160;GlycoMimetics, GMI-1687 is a highly potent E-selectin antagonist that is bioavailable after subcutaneous administration. This second-generation compound has potential application in inflammatory diseases, and the company&#8217;s initial clinical development will focus on SCD. E-selectin is believed to play a major role in vaso-occlusive events (VOEs),</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">a</font><font style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';">group of acute complications that are associated with SCD and include vaso-occlusive pain crises, acute chest syndrome (ACS), stroke, and splenic sequestration. Administration of GMI-1687&#160;by subcutaneous injection, if successfully developed in the clinic, may enable this study drug to be approved as a patient-controlled, point-of-care treatment option. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">About GlycoMimetics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;">GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company&#8217;s <a name="_cp_change_90"></a>scientific approach is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs<a name="_cp_change_92"></a>, known as glycomimetics<a name="_cp_change_94"></a>, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. GlycoMimetics <a name="_cp_change_97"></a>is leveraging its differentiated expertise with this scientific approach <a name="_cp_change_98"></a>in order to advance its pipeline of wholly owned drug candidates. The company&#8217;s goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Forward-Looking Statements </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;">This press release contains forward-looking statements. These forward-looking statements may include, but are not limited to, statements regarding the conduct of and <a name="_cp_change_99"></a>timing for data from clinical trials; planned or potential clinical development, regulatory interactions, or submissions; the company&#8217;s collaborations with third parties; and the potential benefits and impact of the company&#8217;s drug candidates. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing&#160;GlycoMimetics, please see the risk factors described in the <a name="_cp_change_101"></a>company&#8217;s Annual Report on Form 10-K filed with the&#160;U.S. Securities and Exchange Commission&#160;(SEC) on&#160;March 27, 2024, and other filings&#160;GlycoMimetics&#160;makes with the&#160;SEC&#160;<font style="white-space:pre-wrap;">from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.  </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investor Contact: </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Argot Partners</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Leo Vartorella </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;">212-600-1902</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;">Glycomimetics@argotpartners.com</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">GlycoMimetics, Inc.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">Condensed Statements of Operations</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">(In thousands, except share and per share data)</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 41.75pt 0pt 41.75pt;"><font style="visibility:hidden;margin:24pt 0pt 18pt 0pt;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.09%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><font style="font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Revenue from collaboration and license agreements</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 10</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 10</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 75</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;">Research and development expense</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 5,289</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 5,891</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 20,072</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 28,391</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;">General and administrative expense</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,312</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,732</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 19,213</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 19,087</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 30pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 30pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 9,601</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 10,623</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 39,285</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 47,478</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (9,591)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (10,623)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (39,275)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (47,403)</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Interest income </p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 512</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 378</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 2,376</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 715</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (9,079)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (10,245)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (36,899)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (46,688)</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Net loss per common share &#8211; basic and diluted</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.14)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.19)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.58)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.89)</font></p></td></tr><tr><td style="vertical-align:bottom;width:41.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding &#8211; basic and diluted</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 64,393,840</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 52,962,011</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 63,342,465</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 52,531,173</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">GlycoMimetics, Inc.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">Balance Sheet Data</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">(In thousands)</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><font style="font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><font style="font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 41,793</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 47,871</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Working capital</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 36,956</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 41,834</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 45,316</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 51,811</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 6,902</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 8,881</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Total stockholders&#39; equity</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 38,414</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 42,930</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>glyc-20240327xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20240327xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !. 6D# 2(  A$! Q$!_\0
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MUL<'(Y##K[Y%>=>#O!_A7Q#I(FO_ !*-*OD)$L$^Q!UX*EC\W&/?.:ZCX?\
M@OPI<^*()M)\237=Y8RB80O!L\P*1D@GJ.>U=6)IX=1J0E'1;6@U;M[W7]3C
MPM3$N=.<97;>MYIW77W>C_(X_4H_%@^(MNMU(I\3[X_+?$6,[?EZ#;T]J[;4
M/$FMV?Q.\-6%Y) ;@PVD=R?LL+.'8#S 'VY ))^Z<<\5!XB_Y."L?^ND'_HL
M4>-/^2\Z/_UTMON_6M')5>12BOX;>W]:&:A*BIN,W_$2W_/S-[XF?%*_TC64
M\/\ A^(2ZFVT22[-Y5F^ZJKW/(//K7/S7'Q6T",7\WFW41(W0[8INN."J\C\
M*JZS>+X(^.#ZEJD1^QR2&19 N?D=-H8>NTY!^AKT_4OBSX6TVT$YU6*ZR0!%
M;?.YS[=L=>?3UXKB<7AX4XT:*FI)-MJ]V^GD=RDL3.K*O7<'%M))VLEU\[F=
MXR\=ZMX<^'EOJDNG"QU>Y98/*<AUA8ACO[]EX!Z$C/3GC_!VK_$6\N]+ODF3
M5-.O7^?>\9C0#[V\J,QG _I@GBN_\7^(O"^H^"3=ZG.MUH]YA8S$#O=L_P
MX(8$'Z8.:\4OKA/AOK5G?>%O$*:E;7 WF)#\P4$?)*O3G/'0]>!Q1@Z<:E*4
M%32DV]TVO2_2P8ZI*E6A4=5N"2VDD_6W6Y].45FZEXBT_18K1]2NH['[4XCC
M$S8^;&<$]NG4\=/45H@A@"#D'D$5\VXM)-K<^I4HMM)ZH^0?V\?^2E?LQ_\
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MW\%_!GQS\+/X?\:Z';ZUIV[S(C)E9;>3&-\4BX9&]P>1P<@D5VU% 'RMI/\
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=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>glyc-20240327.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/26/2024 10:15:47 PM-->
<!--Modified on: 3/26/2024 10:15:47 PM-->
<xsd:schema targetNamespace="http://www.glycomimetics.com/20240327" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:glyc="http://www.glycomimetics.com/20240327" xmlns:cef-pre="http://xbrl.sec.gov/cef-pre/2023">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20240327_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20240327_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/cef/2023" schemaLocation="https://xbrl.sec.gov/cef/2023/cef-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cef-pre/2023" schemaLocation="https://xbrl.sec.gov/cef/2023/cef-2023_pre.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="glyc_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>glyc-20240327_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/26/2024 10:15:47 PM-->
<!--Modified on: 3/26/2024 10:15:47 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="glyc-20240327.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="glyc_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="glyc_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>glyc-20240327_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/26/2024 10:15:47 PM-->
<!--Modified on: 3/26/2024 10:15:47 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="glyc-20240327.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2023/cef-2023.xsd#N2" roleURI="http://xbrl.sec.gov/cef/role/N2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="glyc-20240327.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="glyc_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638470881471258578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_638470881471258578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638470881471258578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_638470881471258578" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638470881471258578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_638470881471258578" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638470881471258578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_638470881471258578" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638470881471258578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638470881471258578" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638470881471258578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638470881471258578" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638470881471258578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_638470881471258578" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638470881471258578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_638470881471258578" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638470881471268596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_638470881471268596" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638470881471268596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_638470881471268596" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638470881471268596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_638470881471268596" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638470881471268596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_638470881471268596" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638470881471268596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_638470881471268596" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638470881471268596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_638470881471268596" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638470881471268596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_638470881471268596" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638470881471268596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638470881471268596" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638470881471268596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_638470881471268596" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638470881471268596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_638470881471268596" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638470881471268596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_638470881471268596" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638470881471278557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638470881471278557" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638470881471278557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_638470881471278557" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638470881471278557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_638470881471278557" order="22" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cef/role/N2" xlink:type="extended" xlink:title="995470 - Disclosure - N-2" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140061283422912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 27,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-36177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GlycoMimetics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1686563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9708 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">243-1201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GLYC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140061283410800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>N-2<br></strong></div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-36177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GlycoMimetics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9708 Medical Center Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">243-1201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M"  ,2'M8O$> R%($  "T$   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)V8;V^K-A3&OXK%IFF3F@+.WW9)I#1IN^@VO5G3[6J;]L(!)[$*F-FF:;[]
MC@F%3)<<>O>F8((??C[G^+'=X5ZJ%[WCW)"W.$KTR-D9DUZ[K@YV/&;Z4J8\
M@5\V4L7,0%-M79TJSL*\4QRYU/-Z;LQ$XHR'^;.E&@]E9B*1\*4B.HMCI@XW
M/)+[D>,[[P^>Q'9G[ -W/$S9EJ^X^2U=*FBYI4HH8IYH(1.B^&;D3/SK&]JQ
M'?(W?A=\KT_NB1W*6LH7VYB'(\>S1#SB@;$2#"ZO?,JCR"H!QS^%J%-^TW8\
MO7]7O\L'#X-9,\VG,OHB0K,;.0.'A'S#LL@\R?TOO!A0U^H%,M+Y7[(_OMOI
M."3(M)%QT1D(8I$<K^RM",1)A[9_I@,M.M"<^_BAG'+&#!L/E=P39=\&-7N3
M#S7O#7 BL5E9&06_"NAGQC,99!!D0U@2DMO$"',@\^28;8C:T#7P$?NJ&Q2"
M-T=!>D9PP=0EH?T+0CW:^6]W%]A*0%H"TERO_?\ R5^3M38*DOMW'>M1NU.O
M;2O^6J<LX",'2EIS]<J=\0_?^3WO9X2\79*W,?6*_/F0\CHXO/N@]0F!Z)00
MG8]!++D2TD8P)% HM3RX4IG8ILQV2[0N*KCB0::$$5R326#(G8@X><SB-5=U
M<+B6Y_FM=L_O]Q&N7LG50[6*(GOB6V$K"V+WR.+:@.$Z]]$AD NP,","?0%%
M&UPB=/V2KO\1.E"3*I4JGP079&4@IT0J,I598M0!KF$M,BX^NT4(!R7AX".$
MS^R-S$,H/;$1P7&NGL\NKNCU6GYOT.OVV@C>58EW]1&\21C"E(>\%#?D =XC
MGY/:J.&*5WUO0!8\A&%&9 HCYHK,%"PV"*WO50;M?1/OU+8@T\]R7V_/N-R3
M#%Y>112A<">KA_]-<&4=+I5\%4E0&\T&S<4,0ZO6#1\U]Z_0EE(;R,^?(CT[
M.1H4J3?H>AA;M3+XN+?G.9S +NH\"BY .RA(M3KXN*D_2%NSRYU,,.]M$*&=
M=LNGGH\158N"CSOY%U@2#$\@,'&<)85SZ%HJ7&C#(HT6>;4>^+B1KV0D EBH
MDBU90'DKP:):'ERED:=: 7S<I9>*MP((#X?Y==Q@\"0$S_F\V9S)'Z[72%8Y
MOX\;]5=D<ZTS(&L$Q&4; 2OO]W&K?A8&=AER0WSZX_HG4FQ!#K5,N)*M3UC2
M5@;\]()\[UW"%H2D3)%7%F48+*V<G^)6_:Q8:(MN=8C7LK;D&@3N'_Z88B25
MS5/<DM_C1&[?@AU+MOSLEJA!Z'&RFDU^Q9A.S@4?\O?;F*NMC=(]*)B=]8V4
M);49;1!LJC):V3O%W;E LUL!!?8ZA^)_(Y]X/10NY4%9T6Z[-[C"R"J_I[A5
M3V!6AOG,O(O8MI8'%S@;)/?D#&K/\W!<@+1H$O$-"'F7?7!K=3PB'QM&IOFQ
M="T-''+SVQUG8!/V!?A](Z5Y;]B3;OF/BO&_4$L#!!0    (  Q(>UBD@C8>
M(P,  ' *   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULE99K;]HP%(;_
MBI5)^U2:"_<.(E%Z6=72(>@V:=,^F.0 5AT[LPV4?[_C0 .3@MM^@-B.W]>/
M;R>GMY'J62\!#'G)N-!];VE,?N'[.EE"1O6YS$'@F[E4&35850M?YPIH6H@R
M[D=!T/(SRH07]XJVL8I[<F4X$S!61*^RC*KM)7"YZ7NA]]HP88NEL0U^W,OI
M J9@ON=CA36_=$E9!D(S*8B">=\;A!>78<,*BAX_&&ST49G8J<RD?+:5N[3O
M!98(."3&6E!\K&$(G%LGY/B[-_7*,:WPN/SJ?E-,'B<SHQJ&DO]DJ5GVO8Y'
M4IC3%3<3N?D*^PDUK5\BN2[^R6;7M][P2++21F9[,1)D3.R>]&6_$$>"J'5"
M$.T%4<&]&ZB@O**&QCTE-T39WNAF"\54"S7",6%W96H4OF6H,_%C+>KY!HUL
MU4_VHLN=*#HA&E%U3J+V&8F"J/&_W,?Q2XBHA(@*O_H)OZ%<@R*_!S-M%&[3
MGRJBG4.CVL&>W0N=TP3Z'AY.#6H-7OSY4]@*OCCXZB5?W>4>7PO#S)8,02 ?
M)W<BA1=R#]LJ3K=3$ 1AU*RW.ET'5J/$:CC-!G@[4OP9<L/IH@K&K9]3KL'!
MT2PYFDZ?*20KQ0P#308)PC .Y'&5S4!5,;F]<'UJ]5;8;CNX6B57R^EU)9-5
ML3Q/VQRJ4-SR3NW> =$N(=KO.3L36#![NI'FD6:5-&Z?6[Y-Y @#HF&)/L,S
MF)P[Z#HE7><]=(,TQ5N#MOL"><!^Y)NHY'0[=MM!AXP@90G>%'MC\&9?*8R\
M#MIN2=O]$.W0UJ0B3W(CJDC=;A.9/*\9YRZR,#C$T>!#;%-##5BXL9)K)I+*
MI7S#<W3E0CL*\>&'T,92&]R<7RPG0YE6@[D=HZ#3#%QLA\@?.@-W7&SA /.)
MTRAN@ZCA!#F$^- =F1^D/;#CI12NX/6&2=2HU\(H"%U$A^@>NL/S?MNN,U +
M)A;D%AW,$M<IRZFH_/:\87@RWOM'^8/-Q?#[CB-JPF&.1L%Y&V.VVJ4WNXJ1
M>9%2S*3!!*4H+C$E!&4[X/NYE.:U8K.4,LF,_P%02P,$%     @ #$A[6)^@
M&_"Q @  X@P   T   !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8
MMD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2
M_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQD
MB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G
M8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E
M#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M
M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5<D].)3"6T@
ML-5)](1&,80)"L2_C!9B7X2]_:VPI!&/QGWL_&[TH'_OC./WEE>B'_2^FO-C
MT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0<O(%;2AZY=>)P:?EA6;/C
MO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%P<T:L#.EL)7(0;^A7N
M5WGF0/:=D$[H43N*LN3ZQ3GUX1W;^PO\*KY?7_**==+M9G!#S_(77HI.Y?.J
M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ #$A[6)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M/Z*A[.9V<L>KZK2^9^S5OCA5C5L8?]#B"U!+ P04    "  ,2'M8C?<L6K0
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MJW3:^#-?#>_)YA-02P$"% ,4    "  ,2'M8!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  Q(>UC'
MKC!-[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    (  Q(>UB97)PC$ 8  )PG   3              "  <T!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ #$A[6+Q'@,A2!
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M<R\N<F5L<U!+ 0(4 Q0    (  Q(>U@-8>"'4 $  ,4"   /
M  "  ;03  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  ,2'M8C?<L6K0
M  ") @  &@              @ $Q%0  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    "  ,2'M8;J<DO!X!  !7!   $P
M@ $=%@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "@ * (0"  !L%P
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="glyc-20240327x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="glyc-20240327x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995470 - Disclosure - N-2</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cef/role/N2</Role>
      <ShortName>N-2</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>glyc-20240327.xsd</File>
    <File>glyc-20240327_lab.xml</File>
    <File>glyc-20240327_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="glyc-20240327x8k.htm">glyc-20240327x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "glyc-20240327x8k.htm": {
   "nsprefix": "glyc",
   "nsuri": "http://www.glycomimetics.com/20240327",
   "dts": {
    "schema": {
     "local": [
      "glyc-20240327.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/2006/xbrldi-2006.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/cef/2023/cef-2023.xsd",
      "https://xbrl.sec.gov/cef/2023/cef-2023_pre.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_lab.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "glyc-20240327_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "glyc-20240327_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "glyc-20240327x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 208,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20240327x8k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20240327x8k.htm",
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/cef/role/N2",
     "longName": "995470 - Disclosure - N-2",
     "shortName": "N-2",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA",
      "name": "dei:EntityFileNumber",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20240327x8k.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "cef_AcquiredFundFeesAndExpensesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AcquiredFundFeesAndExpensesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AcquiredFundFeesAndExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AcquiredFundFeesAndExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AcquiredFundFeesEstimatedNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AcquiredFundFeesEstimatedNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees Estimated, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AcquiredFundIncentiveAllocationNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AcquiredFundIncentiveAllocationNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Incentive Allocation, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Total Annual Expenses, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "cef_AllRisksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AllRisksMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Risks:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualCoverageReturnRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualCoverageReturnRatePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Coverage Return Rate [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualDividendPayment": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualDividendPayment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualDividendPaymentCurrent": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualDividendPaymentCurrent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Current"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualDividendPaymentInitial": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualDividendPaymentInitial",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Initial"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualExpensesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Expenses [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualInterestRateCurrentPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualInterestRateCurrentPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Current [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualInterestRateInitialPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualInterestRateInitialPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Initial [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualInterestRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualInterestRatePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "cef_BasisOfTransactionFeesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "BasisOfTransactionFeesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Transaction Fees, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_BdcFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "BdcFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BDC File Number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8"
     ]
    },
    "cef_BusinessDevelopmentCompanyFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "BusinessDevelopmentCompanyFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Development Company [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_CapitalStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "CapitalStockTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r14"
     ]
    },
    "cef_DistributionServicingFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "DistributionServicingFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution/Servicing Fees [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_DistributionsMayReducePrincipalTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "DistributionsMayReducePrincipalTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributions May Reduce Principal [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_DividendAndInterestExpensesOnShortSalesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "DividendAndInterestExpensesOnShortSalesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend and Interest Expenses on Short Sales [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_DividendExpenseOnPreferredSharesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "DividendExpenseOnPreferredSharesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Expenses on Preferred Shares [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r14"
     ]
    },
    "cef_DividendReinvestmentAndCashPurchaseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "DividendReinvestmentAndCashPurchaseFees",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Reinvestment and Cash Purchase Fees"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.glycomimetics.com/20240327",
     "localname": "DocumentAndEntityInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "cef_EffectsOfLeveragePurposeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "EffectsOfLeveragePurposeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage, Purpose [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_EffectsOfLeverageTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "EffectsOfLeverageTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_EffectsOfLeverageTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "EffectsOfLeverageTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "cef_ExpenseExampleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ExpenseExampleTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ExpenseExampleYear01": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ExpenseExampleYear01",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Year 01"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ExpenseExampleYears1to10": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ExpenseExampleYears1to10",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 10"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ExpenseExampleYears1to3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ExpenseExampleYears1to3",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 3"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ExpenseExampleYears1to5": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ExpenseExampleYears1to5",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 5"
       }
      }
     },
     "auth_ref": []
    },
    "cef_FeeTableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "FeeTableAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Table [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_FinancialHighlightsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "FinancialHighlightsAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Highlights [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_GeneralDescriptionOfRegistrantAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "GeneralDescriptionOfRegistrantAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Description of Registrant [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_HighestPriceOrBid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "HighestPriceOrBid",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid"
       }
      }
     },
     "auth_ref": []
    },
    "cef_HighestPriceOrBidNav": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "HighestPriceOrBidNav",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, NAV"
       }
      }
     },
     "auth_ref": []
    },
    "cef_HighestPriceOrBidPremiumDiscountToNavPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "HighestPriceOrBidPremiumDiscountToNavPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_IncentiveAllocationMaximumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "IncentiveAllocationMaximumPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Maximum [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_IncentiveAllocationMinimumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "IncentiveAllocationMinimumPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Minimum [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_IncentiveAllocationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "IncentiveAllocationPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_IncentiveFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "IncentiveFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Fees [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_InterestExpensesOnBorrowingsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "InterestExpensesOnBorrowingsPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expenses on Borrowings [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestRateRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestRateRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Rate Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_IntervalFundFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "IntervalFundFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interval Fund [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r13"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "cef_InvestmentObjectivesAndPracticesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "InvestmentObjectivesAndPracticesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Objectives and Practices [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LatestNav": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LatestNav",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest NAV (Deprecated 2023-01-31)"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LatestPremiumDiscountToNavPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LatestPremiumDiscountToNavPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LatestSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LatestSharePrice",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Share Price (Deprecated 2023-01-31)"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LoanServicingFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LoanServicingFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Servicing Fees [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtDividendsAndCovenantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtDividendsAndCovenantsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Dividends and Covenants [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Issuance and Substitution [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtPrincipal",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Principal"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtStructuringTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtStructuringTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Structuring [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Title [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LowestPriceOrBid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LowestPriceOrBid",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LowestPriceOrBidNav": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LowestPriceOrBidNav",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, NAV"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LowestPriceOrBidPremiumDiscountToNavPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LowestPriceOrBidPremiumDiscountToNavPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fee not based on Net Assets, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ManagementFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ManagementFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fees [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetAssetValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetAssetValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NAV Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "cef_NetExpenseOverAssetsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "NetExpenseOverAssetsPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Expense over Assets [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_NewCefOrBdcRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "NewCefOrBdcRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New CEF or BDC Registrant [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r13"
     ]
    },
    "cef_NoPublicTradingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "NoPublicTradingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Public Trading [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "cef_NoTradingHistoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "NoTradingHistoryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading History [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherAnnualExpense1Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherAnnualExpense1Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 1 [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherAnnualExpense2Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherAnnualExpense2Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 2 [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherAnnualExpense3Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherAnnualExpense3Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 3 [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherAnnualExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherAnnualExpensesAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherAnnualExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherAnnualExpensesPercent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherExpensesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherExpensesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherFeederFundExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherFeederFundExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Feeder Fund Expenses [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherMasterFundExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherMasterFundExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Master Fund Expenses [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherSecuritiesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Securities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherSecurityDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherSecurityDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Description [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherSecurityTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherSecurityTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Title [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionExpense1Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionExpense1Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 1 [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionExpense2Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionExpense2Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 2 [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionExpense3Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionExpense3Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 3 [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionExpensesAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionExpensesPercent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionFeesBasisMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionFeesBasisMaximum",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionFeesBasisMaximumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionFeesBasisMaximumPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionFeesBasisNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionFeesBasisNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionFeesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionFeesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OutstandingSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OutstandingSecuritiesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Securities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OutstandingSecurityAuthorizedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OutstandingSecurityAuthorizedShares",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Authorized [Shares]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OutstandingSecurityHeldShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OutstandingSecurityHeldShares",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Held [Shares]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OutstandingSecurityNotHeldShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OutstandingSecurityNotHeldShares",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Not Held [Shares]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OutstandingSecurityTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OutstandingSecurityTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Title [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Liquidating Preference"
       }
      }
     },
     "auth_ref": []
    },
    "cef_PreferredStockRestrictionsArrearageTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "PreferredStockRestrictionsArrearageTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Arrearage [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_PreferredStockRestrictionsOtherTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "PreferredStockRestrictionsOtherTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Other [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_PrimaryShelfFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "PrimaryShelfFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_PrimaryShelfQualifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "PrimaryShelfQualifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf Qualified [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ProspectusLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ProspectusLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ProspectusTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ProspectusTable",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus:"
       }
      }
     },
     "auth_ref": []
    },
    "cef_PurposeOfFeeTableNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "PurposeOfFeeTableNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purpose of Fee Table , Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_RegisteredClosedEndFundFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RegisteredClosedEndFundFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Closed-End Fund [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ReturnAtMinusFivePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ReturnAtMinusFivePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Five [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ReturnAtMinusTenPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ReturnAtMinusTenPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Ten [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ReturnAtPlusFivePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ReturnAtPlusFivePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Five [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ReturnAtPlusTenPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ReturnAtPlusTenPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Ten [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ReturnAtZeroPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ReturnAtZeroPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Zero [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_RightsLimitedByOtherSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RightsLimitedByOtherSecuritiesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Subject to Other than Majority Vote [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_RiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RiskAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_RiskFactorsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RiskFactorsTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk Factors [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_RiskTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RiskTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SalesLoadPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SalesLoadPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Load [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "cef_SecurityDividendsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityDividendsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Dividends [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cef_SecurityLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityLiabilitiesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liabilities [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SecurityLiquidationRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityLiquidationRightsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liquidation Rights [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SecurityObligationsOfOwnershipTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityObligationsOfOwnershipTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Obligations of Ownership [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SecurityPreemptiveAndOtherRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityPreemptiveAndOtherRightsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Preemptive and Other Rights [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SecurityTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Title [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SecurityVotingRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityVotingRightsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Voting Rights [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesAmount",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Amount (Deprecated 2023-01-31)"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Amount"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesAverageMarketValuePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesAverageMarketValuePerUnit",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Average Market Value per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Averaging Method, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesCoveragePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesCoveragePerUnit",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Coverage per Unit (Deprecated 2023-01-31)"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesCvgPerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesCvgPerUnit",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Coverage per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesHeadingsNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesHeadingsNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Headings, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Annualized, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Audited, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Involuntary Liquidating Preference per Unit (Deprecated 2023-01-31)"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SharePriceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SharePriceTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SharePricesNotActualTransactionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SharePricesNotActualTransactionsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Prices Not Actual Transactions [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ShareholderTransactionExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ShareholderTransactionExpensesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Transaction Expenses [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_TotalAnnualExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "TotalAnnualExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Annual Expenses [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "cef_UnderwritersCompensationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "UnderwritersCompensationPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters Compensation [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_WaiversAndReimbursementsOfFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "WaiversAndReimbursementsOfFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Waivers and Reimbursements of Fees [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_WarrantsOrRightsCalledAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "WarrantsOrRightsCalledAmount",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Amount"
       }
      }
     },
     "auth_ref": []
    },
    "cef_WarrantsOrRightsCalledPeriodDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "WarrantsOrRightsCalledPeriodDate",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Period [Date]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_WarrantsOrRightsCalledTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "WarrantsOrRightsCalledTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Title"
       }
      }
     },
     "auth_ref": []
    },
    "cef_WarrantsOrRightsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "WarrantsOrRightsExercisePrice",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001558370-24-004015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-004015-xbrl.zip
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ME<Z9FVDLU0H.2B?)R^/#GXYE .>,[\#;I2ICS6B\DM\2$%ANTP!L-%X14N_
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MJ"A'WQ^O\)*Y)I#S$H8V<-8'?KA./Q>#4GLW\/1RZ'<&3QZ:[ 502P,$%
M  @ #4A[6! @$,6_!   Z"D  !4   !G;'EC+3(P,C0P,S(W7W!R92YX;6S=
MFEUOXC@4AN]'VO_@S5Z')%#*A]J.*--9H>D':AG-:&]&)C%@K6-'MBGP[]<.
M,0620%CM!H4;"/'KD_/Z,4YRDIO/RY" =\0%9O36\FJN!1#U68#I]-::RXG=
MMC[?_?;IYG?;_GG_^@@"YL]#1"7P.8(2!6"!Y0R,6!1!"IX0YY@0<,]Q,$4
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MR9^I#$V=9"4%F4&V=7&Y^5R4.,DZMWTDHYC[>7'>,+JH#SG+\0/H&).J6*.
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M;6J,_2,98V/V'E4^LC#7N3-P+7.!;V?BO,GIKCDF?[I!WS[X'U!+ P04
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M2]=\K\\\-Q[WK6;S[\=3[KI>,*K[8AC#)PV[-_\L]$;C^8=2;ZX?"I_'WK7
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MP*30CWN/CQO<, $7  ,@E:9$^N(;+E(7+:,NREH3\X;EO1M8R9$3@8@!J<-
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M9(*W@3H#B8..H H&.H@?Q"_/?$AE'_K>1 $^QNRY2K[+*1HZ<WG D@#=S$
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M47?5PF/9#G&)H3'CNE8+'V7/Q%!-[F&)4,%2A<R^QE@4." BQ+Y@1P:8#\<
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M>'0Q'.9T/Q"^'GR@S8^A&G( 6ZS/1SH/A["PE8U[0:Q/6X$;1:"4&YY,!4R
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MIJX2\)I/@]ZS:IK=@Y,C<69.\//>X=XC8=:"U?:R/'NZE.EWIFIG6%H/\*Q
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MEWZ44:0/L9)3H0^PVO*,>X59AB:+;V^_^'K(W18@?-.K'?:L?4J1[V#'^&[
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M+'$L<2SECBL&'LHVT]3PW9P:OA. HD3T0_QP@M,]G6X"%.70:,+QKDTXW@U
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M,S(W7VQA8BYX;6Q02P$"% ,4    "  -2'M8$" 0Q;\$  #H*0  %0
M        @ %-!@  9VQY8RTR,#(T,#,R-U]P<F4N>&UL4$L! A0#%     @
M#4A[6-D'UNW.%@  F*X  !0              ( !/PL  &=L>6,M,C R-# S
M,C=X.&LN:'1M4$L! A0#%     @ #4A[6"JBX;-R)   DD8" !@
M     ( !/R(  &=L>6,M,C R-# S,C=X97@Y.60Q+FAT;5!+!08     !0 %
+ $T!  #G1@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>glyc-20240327x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="glyc-20240327.xsd" xlink:type="simple"/>
    <context id="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2024-03-27</startDate>
            <endDate>2024-03-27</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Tc_OTJ1yVZyj06FHXL-gT8HRA_2_1">0001253689</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Tc_QuxbPFNSTkKIKayAtTETFg_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Narr_j1yO9H9iNke32vRcZxm-lA">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Narr_y8Z8T9oZdUODH-3Cok_SrA">2024-03-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Narr_FTgLSYEw3UiqE6yvlu9Uaw">GlycoMimetics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Tc_p3_kJjosNkOWD3walENONg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Tc_dlutGaub7k2gJJcBNaOKdg_1_2">001-36177</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Tc_BS2pV-ulfEGwZp45lrVXZg_1_4">06-1686563</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Narr_WGj3rc7fwk642pLIxahNYg">9708 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Narr_KbV90nSDMkWi6GWqSoxEZw">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Narr_GCI8QYqFpkWmyv1bS7c7iQ">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Narr_mcIuUwnc8E2tPp50DEFpGQ">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Narr_GVdFfEy3t0CYFDc85yh6lQ">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Narr_EZTOlT5KkEC5jjKmy6qmug">243-1201</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Narr_AG34YLuW0USB1KupYYlyLQ">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Narr_RHSZuEgflUyw_bl6-KfFIw">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Narr_FgPYo04JeUqcJEx0rAy1wg">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Narr_zJKno4X0Z06NnCG2e9v30A">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Tc_kbSrr_hdEEG1rxp-XlrkFQ_2_0">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Tc_v2k4bQqCmkG5fUmV-OsrcQ_2_1">GLYC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Tc_5v5501SSL0ukVXumz4uCig_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_3_27_2024_To_3_27_2024_91Cgj-JcJk6bFG3afcCbYA"
      id="Narr_G41F5W6LHkiBAx-YJM3q7Q">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
